Welcome to our dedicated page for Silence Therapeutics Plc SEC filings (Ticker: SLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silence Therapeutics plc (Nasdaq: SLN) SEC filings page brings together the company’s regulatory disclosures as a global clinical-stage biotechnology issuer. Through documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, Silence provides detailed information on its siRNA-based pipeline, financial condition and governance.
In its filings and furnished press releases, the company discusses the development of divesiran, a first-in-class siRNA candidate for polycythemia vera (PV), including Phase 1 and Phase 2 SANRECO study design, clinical data highlights and regulatory designations such as U.S. FDA Fast Track and Orphan Drug status for PV. Filings also reference other programs from the mRNAi GOLD™ platform, including zerlasiran (SLN360) for cardiovascular disease, SLN312 licensed to AstraZeneca and SLN548 for complement-mediated diseases, as well as early extra-hepatic siRNA targeting efforts.
Silence’s periodic reports provide quantitative data on research and development expenses, general and administrative costs, net losses, cash and short-term investment balances and contract liabilities. Risk factor sections and management commentary outline uncertainties related to clinical development, regulatory approvals, collaborations, manufacturing and intellectual property.
Current reports on Form 8-K document material events such as quarterly and annual financial results, completion of clinical trial enrollment milestones, leadership and Board changes, director resignations, and outcomes of shareholder votes at the annual general meeting. These filings also confirm that the company’s American Depositary Shares, each representing three ordinary shares, are listed on The Nasdaq Stock Market LLC under the symbol SLN.
On Stock Titan, SEC filings for SLN are updated in near real time from EDGAR, and AI-powered summaries help explain the key points in lengthy documents. Users can quickly scan 10-K and 10-Q reports, review 8-K event disclosures and track how Silence Therapeutics’ siRNA programs, financial profile and governance structure evolve over time.
Silence Therapeutics plc (SLN) – Form 4 insider purchase
On 17 and 18 June 2025, 10% shareholder Richard Ian Griffiths disclosed open-market purchases totaling 70,448 American Depositary Shares (ADS), coded “P”. The transactions were executed at $5.29 and $5.69 per ADS, representing an estimated cash outlay of roughly $0.39 million.
Because each ADS is immediately convertible into three ordinary shares at no additional cost, the buys expand Griffiths’ economic exposure by about 211,344 ordinary shares. His directly held ADS position rose from 11,392,779 to 11,431,828.
The filing did not reference a Rule 10b5-1 trading plan, suggesting discretionary purchases. No insider sales or derivative exercises were reported.
For investors, clustered insider buying by a large, long-tenured holder often serves as a constructive sentiment indicator, especially when executed near multi-year lows (price context not specified in the filing). While modest relative to Griffiths’ total stake, the fresh capital deployment may signal confidence in Silence Therapeutics’ valuation and forthcoming catalysts.